MedDay addresses areas of unmet need in neurological and psychiatric diseases through the brain metabolism. This approach relies on unique clinical and pharmaceutical development expertise in the field of rare inborn errors of metabolism.
MedDay is a biotechnology company developing new drugs for nervous system disorders. The company was founded in 2011 by Frédéric Sedel, MD, PhD (Chief Executive Officer), a leading neurologist and neuroscientist; and Guillaume Brion, MD (Chief Operating Officer), who has 25 years of experience in drug development and clinical research in the pharmaceutical industry. In April 2013, InnoBio, a biotechnology fund managed by BPIFrance, and Sofinnova Partners together invested in MedDay.
Our vision is to:
- Treat neurological diseases and manifestations by treating metabolic pathway modifications.
- Develop compounds that have a known activity in neurological metabolic pathways.
- Focus on fast and meaningful clinical proof of concept.
- Build Intellectual Property based on formulation/use patents.
- Develop strong academic collaborations.
"We believe that, if a drug has an effect on a neurodegenerative disease, we should be able to demonstrate the effect in a small group of patients. Once the proof of concept is established, the results have to be confirmed in properly designed phase 2/3 placebo-controlled studies involving a larger number of patients."Founders of MedDay, Frédéric Sedel and Guillaume Brion
Our ethics :
- MedDay prioritizes diseases of the central nervous system with high unmet medical need.
- We place patients and their families at the heart of our mission: our approach is designed to bring safe and efficacious drugs to patients in a short period of time.
- To achieve this goal, MedDay mitigates the risks of early development by:
- Investigating diseases directly in patients’ cerebrospinal fluid (through the SPECMET platform);
- Using molecules of the pharmacopeia with an acceptable safety profile;
- Focusing on the clinical proof of efficacy before moving to full pharmaceutical development.